Table 3.

In vivo antileishmanial efficacy of UA against L. infantum in an acute infection model of visceral leishmaniasis (VL) in BALB/c. Parasite burden of the control (untreated) group and treated group with UA parenterally administered at 5 mg/kg daily for seven consecutive days. Results are expressed as mean parasite number ± standard deviation in spleen and liver per milligram.

Group	Parasite Burden (Amastigotes/mg Organ (× 103)
	Spleen	Liver
Treated group (with UA)	0.18 ± 0.02 *	0.06 ± 0.01 *
Untreated group (control)	111.84 ± 2.5	27.96 ± 7.8

* Treated control group vs. untreated show significant differences with p-value < 0.05 determined by Mann–Whitney U test.